Source-grounded facts extracted from Perspective Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Perspective Therapeutics, Inc. shareholders approved Advisory vote on frequency of advisory stockholder votes on executive compensation at the 2026-05-27 meeting.
“The stockholders of the Company voted, on a non-binding advisory basis, on how frequently future non-binding advisory votes on the compensation of the Company’s named executive officers should be held. The votes were cast as follows: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 76,479,166 274,495 364,497 165,067 20,599,237”
Perspective Therapeutics, Inc. shareholders approved Ratification of appointment of WithumSmith+Brown, PC as independent registered public accounting firm at the 2026-05-27 meeting.
“The stockholders of the Company ratified the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Perspective Therapeutics, Inc. shareholders approved Election of Directors at the 2026-05-27 meeting.
“The stockholders of the Company elected Lori A. Woods, Heidi Henson, Maya Martinez-Davis, Frank Morich, M.D., Ph.D., Johan (Thijs) Spoor and Robert Froman Williamson, III to the Company’s Board of Directors”
Perspective Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.
“On May 11, 2026, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and providing recent business highlights.”
Perspective Therapeutics, Inc. reported financial results for the year ended December 31, 2025.
“On March 16, 2026, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025 and providing recent business highlights.”
Perspective Therapeutics, Inc. entered into Underwriting Agreement with Piper Sandler & Co. and UBS Securities LLC, as representatives of the underwriters named therein valued at approximately $175 million (effective 2026-02-02).
“On February 2, 2026, Perspective Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. and UBS Securities LLC, as representatives of the underwriters named therein (the “Underwriters”), in connection with its previously announced underwritten offering (the “Offering”) of 39,576,088 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and, in lieu of Shares to certain investors, pre-funded warrants (the “Pre-Funded Warrants”) to purchase 6,598,046 shares of Common Stock.”
Jonathan Hunt changed role as Chief Financial Officer at Perspective Therapeutics, Inc..
“As of the Effective Date, Mr. Jonathan Hunt will no longer serve as the Company’s Chief Financial Officer but will remain in his role as the Company’s Chief Accounting Officer and principal accounting officer.”
Juan Graham was appointed as Chief Financial Officer at Perspective Therapeutics, Inc..
“On January 2, 2025, the Board of Directors (the “Board”) of Perspective Therapeutics, Inc. (the “Company”) appointed Mr. Juan Graham as the Company’s Chief Financial Officer and principal financial officer, in each case effective as of January 6, 2025”
Mark Austin departed as co-principal financial officer and principal accounting officer at Perspective Therapeutics, Inc..
“Mark Austin ceased serving as an executive officer of the Company and as the Company's “co-principal financial officer” and “principal accounting officer” on August 16, 2024.”
Jonathan Hunt changed role as Chief Financial Officer at Perspective Therapeutics, Inc..
“Effective as of the Effective Date, Jonathan Hunt, the Company’s Chief Financial Officer and “co-principal financial officer,” began serving as the Company’s sole “principal financial officer” and “principal accounting officer.””
Mark Austin resigned as Vice President of Finance, Corporate Controller and Corporate Secretary at Perspective Therapeutics, Inc..
“On August 16, 2024 (the “ Effective Date ”), Mark Austin, the Vice President of Finance, Corporate Controller and Corporate Secretary of Perspective Therapeutics, Inc. (the “ Company ”), ceased serving as an executive officer and as the Company’s “co-principal financial officer” and “principal accounting officer.””
Perspective Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 15, 2024, Perspective Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing recent business highlights.”
Perspective Therapeutics, Inc. completed a disposition involving GT Medical Technologies, Inc. for 279,516 shares of GT Medical common stock and certain cash royalty payments for four years based on net sales (closed 2024-04-12).
“the liabilities of Isoray. Pursuant to the terms of, and subject to the conditions specified in, the Asset Purchase Agreement, at the Closing, (i) GT Medical issued to Isoray 279,516 shares of GT Medical’s common stock, par value $0.0001 per share, representing 0.5% of GT Medical’s issued and outstanding capital stock on a fully diluted basis as of the”
Perspective Therapeutics, Inc. engaged WithumSmith+Brown, PC as its auditor.
“Also, on April 5, 2024, the Audit Committee approved the engagement of WithumSmith+Brown, PC ("Withum") as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024, effective immediately”
Perspective Therapeutics, Inc. dismissed Assure CPA, LLC as its auditor.
“on April 5, 2024, the Audit Committee approved the dismissal of Assure CPA, LLC ("Assure") as the Company’s independent registered public accounting firm, effective immediately”
Perspective Therapeutics, Inc. amended Amendment No. 1 to Asset Purchase Agreement with GT Medical Technologies, Inc. valued at Termination date extended from March 31, 2024 to April 30, 2024 (effective 2024-03-28).
“On March 28, 2024, Perspective Therapeutics, Inc. (the “ Company ”), Isoray Medical, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Medical ”), and GT Medical Technologies, Inc., a Delaware corporation (“ GT Medical ”) entered into Amendment No. 1 to Asset Purchase Agreement (the “ Amendment ”), which amends the Asset Purchase Agreement entered into by and among the parties on December 7, 2023 (the “ Agreement ”).”
Perspective Therapeutics, Inc. reported financial results for the year ended December 31, 2023.
“On March 28, 2024, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023”
Perspective Therapeutics, Inc. entered into Placement Agency Agreement with Oppenheimer & Co. Inc. valued at 5.85% of the gross proceeds (effective 2024-03-04).
“The Private Placement was conducted pursuant to a Placement Agency Agreement, dated March 4, 2024 (the “Placement Agency Agreement”), by and between the Company and Oppenheimer & Co. Inc., as representative of the placement agents named therein (the “Placement Agents”).”
Perspective Therapeutics, Inc. entered into Investment Agreement with certain accredited institutional investors valued at approximately $87.4 million (effective 2024-03-04).
“On March 4, 2024, Perspective Therapeutics, Inc. (the “Company”) entered into an investment agreement (the “Investment Agreement”) with certain accredited institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), 92,009,981 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for a purchase price of $0.95 per share, representing the closing price of the Common Stock on March 1, 2024.”
Perspective Therapeutics, Inc. entered into Underwriting Agreement with Oppenheimer & Co. Inc., as representative of the underwriters valued at approximately $69.0 million (effective 2024-01-17).
“On January 17, 2024, Perspective Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Oppenheimer & Co. Inc., as representative of the underwriters named therein (the “Underwriters”), in connection with its previously announced underwritten public offering (the “Public Offering”) of 132,075,218 shares”
Perspective Therapeutics, Inc. reported preliminary financial results for the year ended December 31, 2023.
“The Preliminary Prospectus Supplement contains certain information and preliminary estimates regarding the Company's financial results for the year ended December 31, 2023, which are set forth below.”
Perspective Therapeutics, Inc. entered into Option Agreement with Lantheus valued at $28.0 million (effective 2024-01-08).
“On January 8, 2024, the Company entered into that certain Option Agreement (the “Option Agreement” and together with the Investment Agreement and the APA, the “Agreements”) with Lantheus whereby Lantheus was granted an exclusive option to negotiate an exclusive, worldwide, royalty- and milestone-bearing right and license to [ 212 Pb]VMT-α-NET, the Company’s clinical stage alpha therapy developed for the treatment of neuroendocrine tumors”
Perspective Therapeutics, Inc. entered into Asset Purchase Agreement with Progenics Pharmaceuticals, Inc. valued at $8.0 million (effective 2024-01-08).
“On January 8, 2024, the Company entered into that certain Asset Purchase Agreement (the “APA”) with Progenics Pharmaceuticals, Inc., a Delaware corporation (“Progenics”) and affiliate of Lantheus, pursuant to which the Company will acquire certain assets and the associated lease of Progenics’ radiopharmaceutical manufacturing facility in Somerset, New Jersey for a purchase price of $8.0 million in cash.”
Perspective Therapeutics, Inc. entered into Investment Agreement with Lantheus Alpha Therapy, LLC valued at $33.2 million (effective 2024-01-08).
“On January 8, 2024, Perspective Therapeutics, Inc. (the “Company”) entered into that certain Investment Agreement (the “Investment Agreement”) with Lantheus Alpha Therapy, LLC, a Delaware limited liability company (“Lantheus”), pursuant to which the Company agreed to sell and issue to Lantheus in a private placement transaction (the “Private Placement”) certain shares (the “Shares”) of the Company’s common stock”
Perspective Therapeutics, Inc. entered into Exclusive Patent License Agreement with Mayo Foundation for Medical Education and Research valued at upfront payment of $1 million, milestone payments up to $68 million, single digit royalties on net s (effective 2023-12-31).
“On December 31, 2023, Perspective Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an exclusive patent license agreement (the “ License Agreement ”) with the Mayo Foundation for Medical Education and Research (“ Mayo Clinic ”).”
Perspective Therapeutics, Inc. entered into Asset Purchase Agreement with GT Medical Technologies, Inc. (effective 2023-12-07).
“On December 7, 2023, Isoray Medical, Inc. (“ Medical ”), a Delaware corporation and wholly-owned subsidiary of Perspective Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an Asset Purchase Agreement (the “ Asset Purchase Agreement ”) by and among Medical, the Company, and GT Medical Technologies, Inc., a Delaware corporation (“ GT Medical ”).”
Perspective Therapeutics, Inc. entered into 2024 Agreement with Joint Stock Company «Isotope» (effective 2023-12-05).
“On December 5, 2023, Isoray Medical, Inc. (“Medical”), a wholly-owned subsidiary of Perspective Therapeutics, Inc. (the “Company”), entered into a supply contract (the “2024 Agreement”) with Joint Stock Company «Isotope», a Russian company (“JSC Isotope”).”
Perspective Therapeutics, Inc. entered into At Market Issuance Sales Agreement with Oppenheimer & Co. Inc., B. Riley Securities, Inc. and JonesTrading Institutional Services LLC valued at $50,000,000 (effective 2023-11-17).
“On November 17, 2023, Perspective Therapeutics, Inc. (the “Company”) entered into an At Market Issuance Sales Agreement (the “Agreement”) with Oppenheimer & Co. Inc., B. Riley Securities, Inc. and JonesTrading Institutional Services LLC (each, an “Agent” and together, the “Agents”) to create an “at-the-market” equity program under which the Company from time to time may offer and sell shares (the “ATM Shares”) of its common stock, par value $0.001 per share (“Company Common Stock”), through or to the Agents.”
Perspective Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.
“issued a press release announcing its financial results for the quarter ended September 30, 2023 and providing recent business highlights”
Perspective Therapeutics, Inc. shareholders approved Approval of Second Amended and Restated 2020 Equity Incentive Plan at the 2023-10-06 meeting.
“The stockholders of the Company approved the Amended and Restated Plan.”
Perspective Therapeutics, Inc. shareholders approved Ratification of appointment of Assure CPA, LLC as independent registered public accounting firm at the 2023-10-06 meeting.
“The stockholders of the Company ratified the appointment of Assure CPA, LLC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Perspective Therapeutics, Inc. shareholders approved Election of Directors at the 2023-10-06 meeting.
“The stockholders of the Company elected Lori A. Woods, Heidi Henson, Frank Morich, M.D., Ph.D., Johan (Thijs) Spoor and Robert Froman Williamson, III to the Board to hold office until the Company’s 2024 Annual Meeting of Stockholders and until his or her successor has been elected and qualified.”
Perspective Therapeutics, Inc. reported financial results for second quarter of fiscal 2023 ended June 30, 2023.
“On August 11, 2023, the Company issued a press release announcing its financial results for the second quarter of fiscal 2023 ended June 30, 2023, the text of which is attached hereto as Exhibit 99.1.”
Jennifer Streeter was terminated as Chief Operating Officer and Vice President of Human Resources at Perspective Therapeutics, Inc..
“On July 10, 2023, Perspective Therapeutics, Inc. (the “Company”) terminated the employment of Jennifer Streeter, the Company’s Chief Operating Officer and Vice President of Human Resources, effective immediately.”
Heidi Henson was appointed as Director at Perspective Therapeutics, Inc..
“Following Mr. McCormick’s resignation, effective as of June 1, 2023, the Board appointed Ms. Heidi Henson as a director of the Company to fill the vacant position on the Board and a member of the Audit (as Chairperson) and Compensation committees of the Board.”
Michael McCormick resigned as Director at Perspective Therapeutics, Inc..
“On May 9, 2023, Michael McCormick gave notice of his resignation from the Board of Directors of the Company (the “ Board ”), effective immediately.”
William Cavanagh III was terminated as Chief Research and Development Officer at Perspective Therapeutics, Inc..
“In connection with the termination of William Cavanagh III from his position of Chief Research and Development Officer of Perspective Therapeutics, Inc. (the “ Company ”), as previously disclosed on the Form 8-K filed by the Company on February 10, 2023, the Company, Isoray Medical, Inc. (a wholly-owned subsidiary of the Company), and Mr. Cavanagh entered into a Separation Agreement effective March 10, 2023.”
Perspective Therapeutics, Inc. reported the three months ended December 31, 2022 results: revenue $1.84 million.
“Revenue for the three months ended December 31, 2022 decreased 35% to $1.84 million versus $2.82 million in the prior year comparable period.”
Perspective Therapeutics, Inc.: Name change of the registrant from Isoray, Inc. to Perspective Therapeutics, Inc. via amended and restated certificate of incorporation and bylaws; no substantive change other than name per filing (effective 2023-02-14).
“The only substantive change to the Company’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws is the change of the Company’s corporate name from Isoray, Inc. to Perspective Therapeutics, Inc.”
William Cavanagh III was terminated as Chief Research and Development Officer at Perspective Therapeutics, Inc..
“William Cavanagh III was terminated from his position of Chief Research and Development Officer of the Company on February 7, 2023.”
Perspective Therapeutics, Inc.: The Board approved a change in the Company's fiscal year end from June 30 to December 31, effective immediately (effective 2023-01-31).
“On January 31, 2023, the Board approved a change in the fiscal year end of the Company from June 30 to December 31.”
Perspective Therapeutics, Inc. completed an acquisition involving Viewpoint Molecular Targeting, Inc. (closed 2023-02-03).
“On February 3, 2023 (the " Closing Date "), the Company completed the merger (the " Closing ") of Isoray Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Company (" Merger Sub "), with Viewpoint Molecular Targeting, Inc. (" Viewpoint ") (such transaction being the " Merger ").”
Frank Morich was appointed as Director at Perspective Therapeutics, Inc..
“(iv) Dr. Frank Morich as a director of the Company”
Robert Froman Williamson, III was appointed as Director at Perspective Therapeutics, Inc..
“(iii) Robert Froman Williamson, III as a director of the Company”
Lori A. Woods was appointed as Chairperson of the Board at Perspective Therapeutics, Inc..
“(ii) Lori A. Woods as Chairperson of the Board”
Johan (Thijs) Spoor was appointed as Chief Executive Officer at Perspective Therapeutics, Inc..
“the Board appointed: (i) Johan (Thijs) Spoor as Chief Executive Officer and a director of the Company”
Lori A. Woods resigned as Chief Executive Officer at Perspective Therapeutics, Inc..
“On February 1, 2023, and effective upon the Closing, Lori A. Woods gave notice of her resignation as the Chief Executive Officer of the Company.”
Philip Vitale resigned as Director at Perspective Therapeutics, Inc..
“Alan Hoffmann and Dr. Philip Vitale each gave notice of their resignation from the Board of Directors of the Company (the “ Board ”), effective upon the Closing.”
Alan Hoffmann resigned as Director at Perspective Therapeutics, Inc..
“Alan Hoffmann and Dr. Philip Vitale each gave notice of their resignation from the Board of Directors of the Company (the “ Board ”), effective upon the Closing.”
Perspective Therapeutics, Inc. shareholders approved Approve an amendment to the Company’s Certificate of Incorporation to increase the total number of authorized shares of Common Stock to 750,000,000 at the 2023-01-27 meeting.
“The votes for this proposal were: For Against Abstain Broker Non-Votes 71,844,322 14,571,252 948,682 16,492,269”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.